FATEHIGH SIGNALFINANCIAL10-K

FATE experienced substantially reduced revenue alongside meaningful operational improvements, including reduced R&D spending and improved operating losses, while share count increased to 116.3 million shares.

The company appears to be in a transitional phase with significantly lower revenue generation but demonstrating improved cost discipline through reduced R&D expenses and better operating performance. The addition of more detailed risk factors around clinical trial competition, regulatory funding concerns, and supply chain dependencies suggests management is providing more comprehensive risk disclosure as the company navigates development challenges.

Comparing 2026-02-26 vs 2025-03-05View on EDGAR →
FINANCIAL ANALYSIS

FATE's financial profile shows a mixed picture with revenue declining substantially while operational metrics improved meaningfully. The company reduced R&D spending by 20% to $107.8M and narrowed both operating and net losses by roughly 27-30%. Despite lower revenues, cash position strengthened to $46.6M, though overall balance sheet contracted with stockholders' equity declining 35% to $207.2M and total assets falling 28% to $318.9M, reflecting the operational cash burn and reduced asset base.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-74.1%
$3.5M→$916K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Revenue
P&L
-51.2%
$13.6M→$6.6M

Revenue declined 51.2% — significant demand weakness or market share loss warrants investigation.

Stockholders Equity
Balance Sheet
-35%
$318.7M→$207.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Income
P&L
+29.8%
-$210.3M→-$147.7M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Cash & Equivalents
Balance Sheet
+29.3%
$36.1M→$46.6M

Cash grew 29.3% — improving liquidity position supports investment and shareholder returns.

Current Assets
Balance Sheet
-28.5%
$291.9M→$208.7M

Current assets declined 28.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-27.6%
$440.7M→$318.9M

Total assets contracted 27.6% — asset sales, write-downs, or balance sheet optimization underway.

Net Income
P&L
+26.8%
-$186.3M→-$136.3M

Net income grew 26.8% — bottom-line growth signals improving overall business health.

R&D Expense
P&L
-20.1%
$135.0M→$107.8M

R&D spending cut 20.1% — could signal cost discipline or concerning reduction in innovation investment.

Operating Cash Flow
Cash Flow
+13.7%
-$122.9M→-$106.1M

Operating cash flow grew 13.7% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-05
ADDED
The number of outstanding shares of the registrant s common stock, par value $0.001 per share, as of February 19, 2026 w as 116,263,459 .
Our product candidates and programs represent novel therapeutic approaches to treating disease, and our product candidates may fail to demonstrate the safety, potency, durability, and efficacy necessary to support further development or commercialization, or may cause undesirable side effects or have other properties that could delay or halt their preclinical or clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
We face significant competition in an environment of rapid technological change from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively, including with respect to the recruitment of patients and investigative sites to participate in our clinical trials.
Inadequate funding for the FDA, SEC, the National Institutes of Health and other government agencies, as well as changes in personnel and policy priorities at these agencies, could disrupt such agencies operations and, in turn, hinder our ability to develop or commercialize new products in a timely manner or otherwise negatively impact our business.
We depend on third-party suppliers, including sole source suppliers, for certain equipment and components used in the production of our product candidates, and the loss of suppliers could adversely impact our ability to conduct our clinical trials.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant s common stock, par value $0.001 per share, as of February 25, 2025 w as 114,597,425 .
Our product candidates and programs represent novel therapeutic approaches to treating disease, and our product candidates may cause undesirable side effects or have other properties that could delay or halt their preclinical or clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
We face significant competition in an environment of rapid technological change from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
We depend on third-party suppliers, including sole source suppliers, for certain aspects in the production of our product candidates, the loss of which suppliers could adversely impact our ability to conduct our clinical trials.
Security breaches, loss of data and other disruptions could compromise sensitive information related to our business.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →